Sign In
Buy CLPT
$13.30
+0.93 (+7.52%)
At Close: Jun 03, 2026
Move Over, Magnificent 7: The Frontier 7 Will Redefine Our Future
10:54am, Thursday, 10'th Jul 2025
Key Points in This Article: The Magnificent 7 transformed markets through AI and digital ecosystems, turning a once-pejorative label into a celebrated symbol of innovation and growth.
ClearPoint Neuro: Consumables Growth Is Promising
05:46pm, Friday, 27'th Jun 2025
ClearPoint's fundamentals remain strong, despite recent stock weakness. Consumables growth and an expectation of 15-20 system placements in 2025 are illustrative of this strength. The introduction of
I Missed The Quantum Rally - I Won't Miss The Next One
05:47am, Tuesday, 20'th May 2025
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, progra
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
09:11am, Thursday, 15'th May 2025
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.
ClearPoint Neuro, Inc. (CLPT) Q1 2025 Earnings Call Transcript
10:02pm, Tuesday, 13'th May 2025
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Joseph Burnett - President and Chief Executive Officer Danilo D'Alessandro - Chief F
ClearPoint Neuro, Inc. (CLPT) Reports Q1 Loss, Tops Revenue Estimates
06:35pm, Tuesday, 13'th May 2025
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.16 per share a year ago.
ClearPoint Neuro Reports First Quarter 2025 Results
04:40pm, Tuesday, 13'th May 2025
Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 13, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"),
Wall Street Analysts Believe ClearPoint Neuro (CLPT) Could Rally 102.86%: Here's is How to Trade
11:01am, Tuesday, 13'th May 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 102.9% in ClearPoint Neuro (CLPT). While the effectiveness of this highly sought-after metric is questionable,
ClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at Closing
04:05pm, Monday, 12'th May 2025
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 12, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation t
ClearPoint Neuro: Fundamentals Continue To Strengthen
12:00am, Tuesday, 29'th Apr 2025
ClearPoint continues to make progress in relation to its LITT and operating room expansion efforts. More importantly, ClearPoint's partners continue to provide positive news in relation to their thera
ClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025
08:00am, Friday, 25'th Apr 2025
SOLANA BEACH, CA / ACCESS Newswire / April 25, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the
ClearPoint Neuro: Drug Delivery Prospects Continue To Strengthen
11:18pm, Thursday, 27'th Feb 2025
ClearPoint's Q4 results were soft, although lumpy growth should be expected given the nature of ClearPoint's business. Neurosurgery growth remains robust, and the expansion of preclinical and clinical
ClearPoint Neuro, Inc. (CLPT) Q4 2024 Earnings Call Transcript
07:17pm, Wednesday, 26'th Feb 2025
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Misses Revenue Estimates
06:30pm, Wednesday, 26'th Feb 2025
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.19 per share a year ago.
ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results
04:05pm, Wednesday, 26'th Feb 2025
Achieved Record Revenue for 2024 and Growth of 31%; Reduced 2024 Operational Cash Burn by 35% SOLANA BEACH, CALIFORNIA / ACCESS Newswire / February 26, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the
